Stay updated on Apremilast-Dupilumab Combo in Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.

Latest updates to the Apremilast-Dupilumab Combo in Eczema Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded a dedicated Locations section featuring Massachusetts (Boston, MA) as a study location and removed the prior Massachusetts Locations entry; the page revision was updated from v3.3.2 to v3.3.3, and the HHS Vulnerability Disclosure link in the footer was removed.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedRevision: v3.3.2 replaces v3.2.0 on the page. It is a minor site update and does not modify study details or user actions.SummaryDifference0.1%

- Check47 days agoChange DetectedRemoved the banner noting a lapse in government funding and related operating status; the page no longer displays that notice.SummaryDifference0.4%

- Check61 days agoChange DetectedNo additions or deletions were detected on the page; the study details and content remain unchanged.SummaryDifference0.5%

- Check90 days agoChange Detected- Added a prominent notice about potential outages due to lapse in government funding and updated operating status guidance. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

- Check97 days agoChange DetectedVersion bump from v3.0.2 to v3.1.0. This signals a software update; no other content changes are indicated.SummaryDifference0.1%

Stay in the know with updates to Apremilast-Dupilumab Combo in Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast-Dupilumab Combo in Eczema Clinical Trial page.